Cover Image

Randomized placebo-controlled EPPIC trials of AST-120 in CKD

Reduced GFR in patients with CKD causes systemic accumulation of uremic toxins, which has been correlated with disease progression and increased morbidity. The orally administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption through gastrointestinal sequestration, which may s...

Full description

Saved in:
Bibliographic Details
Main Authors: Schulman, Gerald (Author) , Berl, Tomas (Author) , Beck, Gerald J. (Author) , Remuzzi, Giuseppe (Author) , Ritz, Eberhard (Author) , Arita, Kiyoshi (Author) , Kato, Akira (Author) , Shimizu, Miho (Author)
Format: Article (Journal)
Language:English
Published: June 30, 2015
In: Journal of the American Society of Nephrology
Year: 2015, Volume: 26, Issue: 7, Pages: 1732-1746
ISSN:1533-3450
DOI:10.1681/ASN.2014010042
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1681/ASN.2014010042
Verlag, lizenzpflichtig, Volltext: https://jasn.asnjournals.org/content/26/7/1732
Get full text
Author Notes:Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Kiyoshi Arita, Akira Kato, and Miho Shimizu

MARC

LEADER 00000caa a2200000 c 4500
001 172514106X
003 DE-627
005 20230426103350.0
007 cr uuu---uuuuu
008 200720s2015 xx |||||o 00| ||eng c
024 7 |a 10.1681/ASN.2014010042  |2 doi 
035 |a (DE-627)172514106X 
035 |a (DE-599)KXP172514106X 
035 |a (OCoLC)1341346979 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schulman, Gerald  |e VerfasserIn  |0 (DE-588)1156570530  |0 (DE-627)1019371803  |0 (DE-576)502265256  |4 aut 
245 1 0 |a Randomized placebo-controlled EPPIC trials of AST-120 in CKD  |c Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Kiyoshi Arita, Akira Kato, and Miho Shimizu 
264 1 |c June 30, 2015 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online ahead of print. P 
500 |a Gesehen am 20.07.2020 
520 |a Reduced GFR in patients with CKD causes systemic accumulation of uremic toxins, which has been correlated with disease progression and increased morbidity. The orally administered spherical carbon adsorbent AST-120 reduces systemic toxin absorption through gastrointestinal sequestration, which may slow disease progression in these patients. The multinational, randomized, double-blind, placebo-controlled Evaluating Prevention of Progression in CKD (EPPIC)-1 and EPPIC-2 trials evaluated the effects of AST-120 on the progression of CKD when added to standard therapy. We randomly assigned 2035 adults with moderate to severe disease (serum creatinine at screening, 2.0-5.0 mg/dl for men and 1.5-5.0 mg/dl for women) to receive either placebo or AST-120 (9 g/d). The primary end point was a composite of dialysis initiation, kidney transplantation, and serum creatinine doubling. Each trial continued until accrual of 291 primary end points. The time to primary end point was similar between the AST-120 and the placebo groups in both trials (EPPIC-1: hazard ratio, 1.03; 95% confidence interval, 0.84 to 1.27; P=0.78) (EPPIC-2: hazard ratio, 0.91; 95% confidence interval, 0.74 to 1.12; P=0.37); a pooled analysis of both trials showed similar results. The estimated median time to primary end points for the placebo groups was 124 weeks for power calculations, but actual times were 189.0 and 170.3 weeks for EPPIC-1 and EPPIC-2, respectively. Thus, disease progression was more gradual than expected in the trial populations. In conclusion, the benefit of adding AST-120 to standard therapy in patients with moderate to severe CKD is not supported by these data. 
650 4 |a CKD 
650 4 |a creatinine 
650 4 |a GFR 
650 4 |a randomized controlled trials 
700 1 |a Berl, Tomas  |e VerfasserIn  |4 aut 
700 1 |a Beck, Gerald J.  |e VerfasserIn  |4 aut 
700 1 |a Remuzzi, Giuseppe  |d 1949-  |e VerfasserIn  |0 (DE-588)1137964952  |0 (DE-627)895254832  |0 (DE-576)492285829  |4 aut 
700 1 |a Ritz, Eberhard  |d 1938-2023  |e VerfasserIn  |0 (DE-588)106673386  |0 (DE-627)610528866  |0 (DE-576)311552501  |4 aut 
700 1 |a Arita, Kiyoshi  |e VerfasserIn  |4 aut 
700 1 |a Kato, Akira  |e VerfasserIn  |4 aut 
700 1 |a Shimizu, Miho  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 1990  |g 26(2015), 7, Seite 1732-1746  |h Online-Ressource  |w (DE-627)324616481  |w (DE-600)2029124-3  |w (DE-576)094113769  |x 1533-3450  |7 nnas 
773 1 8 |g volume:26  |g year:2015  |g number:7  |g pages:1732-1746  |g extent:15  |a Randomized placebo-controlled EPPIC trials of AST-120 in CKD 
856 4 0 |u https://doi.org/10.1681/ASN.2014010042  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://jasn.asnjournals.org/content/26/7/1732  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200720 
993 |a Article 
994 |a 2015 
998 |g 106673386  |a Ritz, Eberhard  |m 106673386:Ritz, Eberhard  |d 910000  |d 910100  |e 910000PR106673386  |e 910100PR106673386  |k 0/910000/  |k 1/910000/910100/  |p 5 
999 |a KXP-PPN172514106X  |e 3725926239 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"15 S."}],"relHost":[{"part":{"extent":"15","text":"26(2015), 7, Seite 1732-1746","volume":"26","pages":"1732-1746","issue":"7","year":"2015"},"titleAlt":[{"title":"JASN"}],"pubHistory":["1.1990 -"],"recId":"324616481","corporate":[{"role":"aut","display":"American Society of Nephrology","roleDisplay":"VerfasserIn"}],"language":["eng"],"disp":"American Society of NephrologyJournal of the American Society of Nephrology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 19.08.24"],"title":[{"subtitle":"JASN","title":"Journal of the American Society of Nephrology","title_sort":"Journal of the American Society of Nephrology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2029124-3"],"eki":["324616481"],"issn":["1533-3450"]},"origin":[{"publisherPlace":"Washington, DC ; [Erscheinungsort nicht ermittelbar]","publisher":"American Society of Nephrology ; Ovid","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}]}],"name":{"displayForm":["Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Kiyoshi Arita, Akira Kato, and Miho Shimizu"]},"origin":[{"dateIssuedDisp":"June 30, 2015","dateIssuedKey":"2015"}],"id":{"eki":["172514106X"],"doi":["10.1681/ASN.2014010042"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online ahead of print. P","Gesehen am 20.07.2020"],"language":["eng"],"recId":"172514106X","person":[{"given":"Gerald","family":"Schulman","role":"aut","display":"Schulman, Gerald","roleDisplay":"VerfasserIn"},{"display":"Berl, Tomas","roleDisplay":"VerfasserIn","role":"aut","family":"Berl","given":"Tomas"},{"given":"Gerald J.","family":"Beck","role":"aut","roleDisplay":"VerfasserIn","display":"Beck, Gerald J."},{"family":"Remuzzi","given":"Giuseppe","roleDisplay":"VerfasserIn","display":"Remuzzi, Giuseppe","role":"aut"},{"given":"Eberhard","family":"Ritz","role":"aut","roleDisplay":"VerfasserIn","display":"Ritz, Eberhard"},{"roleDisplay":"VerfasserIn","display":"Arita, Kiyoshi","role":"aut","family":"Arita","given":"Kiyoshi"},{"given":"Akira","family":"Kato","role":"aut","display":"Kato, Akira","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Shimizu, Miho","given":"Miho","family":"Shimizu"}],"title":[{"title":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD","title_sort":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD"}]} 
SRT |a SCHULMANGERANDOMIZED3020 

Similar Items